Antiviral therapy and risk for hepatocellular carcinoma in chronic viral hepatitis


如何引用文章

全文:

详细

Hepatocellular carcinoma (HCC) is one of the most common human malignancies in incidence and mortality, which develops in the majority of patients in the stage of cirrhosis. Because of the major etiological role of hepatitis viruses, the prevention of HCC is vaccination against hepatitis B virus and successful antiviral therapy for chronic hepatitis B and C.

全文:

Противовирусная терапия и риск развития гепатоцеллюлярной карциномы при хроническом вирусном гепатите. - Аннотация. Гепатоцеллюлярная карцинома (ГЦК) - одна из самых распространенных по частоте и летальности злокачественных опухолей человека, которая развивается в большинстве случаев у больных на стадии цирроза печени. Ввиду основной этиологической роли вирусов гепатита профилактика развития ГЦК заключается в вакцинации против вируса гепатита В и успешной противовирусной терапии хронического гепатита В и С.
×

作者简介

D Abdurakhmanov

Email: abdjamal@mail.ru

参考

  1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
  2. IARC. <http://www-dep.iarc.fr/>; 2011 [accessed 01.11.11].
  3. Sanyal A.J., Yoon S.K., Lencioni R. The Etiology of Hepatocellular Carcinoma and Consequences for treatment. Oncologist 2010; 15 (suppl 4): 14-22.
  4. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1952.
  5. Hassan M.M., Hwang L.Y., Hatten C.J. et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-1213.
  6. Franceschi S., Montella M., Polesel J. et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 2006; 15 (4): 683-689.
  7. Chen C.J., Yang H.I., Su J. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. REVEAL-HBV Study Group. JAMA 2006; 4 (2951): 65-73.
  8. Yang H.I., Yuen M.F., Chan H.L. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-574.
  9. Albanis E., Friedman S.L. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 2001; 5: 315-334.
  10. Gressner O.A., Weiskirchen R., Gressner A.M. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comparative Hepatol 2007; 6: 7-10.
  11. Zois C.D., Baltayiannis G.H., Karayiannis P., Tsianos E.V. Systematic review: hepatic fibrosis-regression with therapy. Aliment Pharmacol Ther 2008; 28: 1175-1187.
  12. Wege H., Brummendorf T.H. Telomerase activation in liver regeneration and hepatocarcinogenesis: Dr. Jekyll or Mr. Hyde? Curr Stem Cell Res Ther 2007; 2: 31-38.
  13. Wiemann S.U., Satyanarayana A., Tsahuridu M. et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002; 16: 935-942.
  14. Carson D.A., Lois A. Cancer progression and p53. Lancet 1995; 346: 1009-1011.
  15. Hoshida Y., Villanueva A., Kobayashi M. et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. NEJM 2008; 359 (19): 1995-2004.
  16. Bedossa P., Poynard T. The French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hepatology 1996; 24: 289-293.
  17. Ishak K., Baptista A., Bianchi L. et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
  18. Knodell R.G., Ishak K.G., Black W.C. et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 4: 431-435.
  19. Castera L., Forns X., Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48 (5): 835-847.
  20. Imbert-Bismut F., Ratziu V., Pieroni L. et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075.
  21. Mommeja-Marin H., Mondou E., Blum M.R., Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic 3HBV infection: analysis and review of the literature. Hepatology 2003; 37 (6): 1309-1319.
  22. Sung J.J., Tsoi K.K., Wong V.W. et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-1077.
  23. Lin S.M., Yu M.L., Lee C.M. et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46 (1): 45-52.
  24. Papatheodoridis G.V., Petraki K., Cholongitas E. et al. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2005; 12 (2): 199-206.
  25. Liaw Y.F., Sung J.Y., Chow W.C. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
  26. Singal A.K., Salameh H., Kuo Y.F., Fontana R.J. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38 (2): 98-106.
  27. Papatheodoridis G.V., Lampertico P., Manolakopoulos S., Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53 (2): 348-356.
  28. Chang T.T., Liaw Y.F., Wu S.S. et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
  29. Mochida S., Takaguchi K., Yokosuka O. et al. Long term efficacy, safety and resistance analyses of entecavir treatment in Japanese nucleoside-naive patients with chronic hepatitis B. J Hepatol 2008; 48 (suppl 2): 262.
  30. Wong G.L., Chan H.L., Mak C.H. et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013, doi: 10.1002/hep.26301.
  31. Hosaka T., Suzuki F., Kobayashi M. et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2012, doi: 10.1002/hep.26180.
  32. Singal A.K., Singh A., Jaganmohan S. et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-199.
  33. Schvarcz R., Glaumann H., Reichard O., Weiland O. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999; 6 (3): 237-242.
  34. Bruno S., Stroffolini T., Colombo M. et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45, 579-587.
  35. Camm C., Di Bona D., Craxà A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Des 2004; 10 (17): 2123-2130.
  36. Mallet V., Gilgenkrantz H., Serpaggi J. et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149 (6): 399-403.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2013

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house